LAUREN P SILVERNAIL Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for LAUREN P SILVERNAIL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of LAUREN P SILVERNAIL. LAUREN P SILVERNAIL is CFO in ISTA PHARMACEUTICALS INC ($ISTA) and Chief Financial Officer in ISTA PHARMACEUTICALS INC ($ISTA) and CFO & CBO in Revance Therapeutics, Inc. ($RVNC) and CFO, CBO & Secretary in Revance Therapeutics, Inc. ($RVNC) and CFO, Secretary & EVP Corp Dev. in Revance Therapeutics, Inc. ($RVNC) and See Remarks in Evolus, Inc. ($EOLS).
Latest Insider Trading Transactions of LAUREN P SILVERNAIL
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, EOLS, ISTA, RVNC
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 01 2021 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Grant | A | 0.00 | 90,000 | 0 | 180,689 | 90.7 K to 180.7 K (+99.24 %) |
Jan 26 2021 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Sell | S | 7.46 | 2,699 | 20,135 | 90,689 | 93.4 K to 90.7 K (-2.89 %) |
May 15 2020 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Grant | A | 0.00 | 40,000 | 0 | 93,388 | 53.4 K to 93.4 K (+74.92 %) |
Jan 24 2020 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Option Exercise | A | 10.19 | 45,000 | 458,550 | 45,000 | |
Jan 24 2020 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Grant | A | 0.00 | 26,000 | 0 | 53,388 | 27.4 K to 53.4 K (+94.93 %) |
May 31 2019 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Sell | S | 13.53 | 2,612 | 35,352 | 27,388 | 30 K to 27.4 K (-8.71 %) |
May 31 2019 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Sell | S | 13.53 | 2,612 | 35,352 | 27,388 | 30 K to 27.4 K (-8.71 %) |
Jan 25 2019 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Option Exercise | A | 16.19 | 45,000 | 728,550 | 45,000 | |
May 31 2018 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Option Exercise | A | 22.44 | 200,000 | 4,488,000 | 200,000 | |
May 31 2018 | EOLS | Evolus, Inc. | SILVERNAIL LAUREN P | See Remarks | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
May 24 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO & CBO | Sell | S | 30.25 | 2,874 | 86,924 | 65,497 | 68.4 K to 65.5 K (-4.20 %) |
Mar 23 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 30.85 | 3,431 | 105,839 | 68,371 | 71.8 K to 68.4 K (-4.78 %) |
Mar 23 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 30.85 | 3,431 | 105,839 | 68,371 | 71.8 K to 68.4 K (-4.78 %) |
Mar 15 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 25,867 | 225,043 | 0 | |
Mar 15 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 31.65 | 1,152 | 36,461 | 71,802 | 73 K to 71.8 K (-1.58 %) |
Mar 15 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 34.50 | 25,867 | 892,412 | 72,954 | 98.8 K to 73 K (-26.18 %) |
Mar 15 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 25,867 | 225,043 | 98,821 | 73 K to 98.8 K (+35.46 %) |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 10,000 | 87,000 | 25,867 | |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 10,000 | 87,000 | 35,867 | |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 32.50 | 10,000 | 325,000 | 72,954 | 83 K to 73 K (-12.05 %) |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 10,000 | 87,000 | 82,954 | 73 K to 83 K (+13.71 %) |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 31.50 | 10,000 | 315,000 | 72,954 | 83 K to 73 K (-12.05 %) |
Mar 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 10,000 | 87,000 | 82,954 | 73 K to 83 K (+13.71 %) |
Feb 16 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 31.75 | 1,136 | 36,068 | 72,954 | 74.1 K to 73 K (-1.53 %) |
Feb 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | A | 29.15 | 48,750 | 1,421,063 | 48,750 | |
Feb 09 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Grant | A | 0.00 | 8,125 | 0 | 74,090 | 66 K to 74.1 K (+12.32 %) |
Jan 30 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 33.50 | 990 | 33,165 | 65,965 | 67 K to 66 K (-1.48 %) |
Jan 03 2018 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | J | 22.99 | 443 | 10,186 | 66,955 | 66.5 K to 67 K (+0.67 %) |
Dec 28 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 17,506 | 152,302 | 45,867 | |
Dec 28 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 17,506 | 152,302 | 66,512 | 49 K to 66.5 K (+35.72 %) |
Nov 09 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 10,000 | 87,000 | 63,373 | |
Nov 09 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 26.83 | 10,000 | 268,267 | 49,006 | 59 K to 49 K (-16.95 %) |
Nov 09 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 10,000 | 87,000 | 59,006 | 49 K to 59 K (+20.41 %) |
Oct 16 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 26.67 | 11,164 | 297,760 | 49,006 | 60.2 K to 49 K (-18.55 %) |
Jul 05 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | J | 18.32 | 604 | 11,064 | 60,170 | 59.6 K to 60.2 K (+1.01 %) |
May 31 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | M | 8.70 | 23,000 | 200,100 | 73,373 | |
May 31 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | M | 8.70 | 23,000 | 200,100 | 59,566 | 36.6 K to 59.6 K (+62.90 %) |
May 24 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | S | 20.20 | 1,793 | 36,212 | 36,566 | 38.4 K to 36.6 K (-4.67 %) |
Mar 17 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 19.20 | 1,269 | 24,366 | 38,359 | 39.6 K to 38.4 K (-3.20 %) |
Jan 30 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | A | 19.70 | 60,000 | 1,182,000 | 60,000 | |
Jan 30 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Sell | D | 20.00 | 1,063 | 21,260 | 39,628 | 40.7 K to 39.6 K (-2.61 %) |
Jan 30 2017 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Grant | A | 0.00 | 10,000 | 0 | 40,691 | 30.7 K to 40.7 K (+32.58 %) |
Jul 05 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | J | 11.56 | 749 | 8,658 | 30,691 | 29.9 K to 30.7 K (+2.50 %) |
May 23 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 17.11 | 1,753 | 29,994 | 29,942 | 31.7 K to 29.9 K (-5.53 %) |
Feb 04 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Option Exercise | A | 20.32 | 60,000 | 1,219,200 | 60,000 | |
Feb 04 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Grant | A | 0.00 | 10,000 | 0 | 31,695 | 21.7 K to 31.7 K (+46.09 %) |
Feb 01 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Payment of Exercise | F | 20.30 | 1,063 | 21,579 | 21,695 | 22.8 K to 21.7 K (-4.67 %) |
Jan 04 2016 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, CBO & Secretar ... | Buy | J | 27.00 | 339 | 9,153 | 22,758 | 22.4 K to 22.8 K (+1.51 %) |
Jul 02 2015 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, Secretary & EV ... | Buy | J | 14.16 | 633 | 8,963 | 633 | 0 to 633 |
May 21 2015 | RVNC | Revance Therapeuti ... | SILVERNAIL LAUREN P | CFO, Secretary & EV ... | Payment of Exercise | F | 25.94 | 1,753 | 45,473 | 21,517 | 23.3 K to 21.5 K (-7.53 %) |
Feb 18 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Sell | D | 3.96 | 513 | 2,031 | 58,120 | 58.6 K to 58.1 K (-0.87 %) |
Feb 10 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Sell | D | 3.59 | 962 | 3,454 | 58,633 | 59.6 K to 58.6 K (-1.61 %) |
Feb 05 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Sell | D | 3.60 | 989 | 3,560 | 59,595 | 60.6 K to 59.6 K (-1.63 %) |
Feb 04 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 3.63 | 15,174 | 55,082 | 15,174 | |
Feb 04 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 3.63 | 31,826 | 115,528 | 31,826 | |
Feb 04 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Grant | A | 0.00 | 9,000 | 9 | 60,584 | 51.6 K to 60.6 K (+17.45 %) |
Feb 04 2010 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Sell | D | 3.63 | 769 | 2,791 | 51,584 | 52.4 K to 51.6 K (-1.47 %) |
Feb 05 2009 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 1.04 | 21,537 | 22,398 | 21,537 | |
Feb 05 2009 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 1.04 | 25,463 | 26,482 | 25,463 | |
Feb 05 2009 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Grant | A | 0.00 | 9,000 | 9 | 52,353 | 43.4 K to 52.4 K (+20.76 %) |
Dec 11 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | P | 0.63 | 17,000 | 10,698 | 43,353 | 26.4 K to 43.4 K (+64.51 %) |
Feb 20 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Payment of Exercise | F | 4.56 | 500 | 2,280 | 26,269 | 26.8 K to 26.3 K (-1.87 %) |
Feb 12 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 4.46 | 29,097 | 129,773 | 29,097 | |
Feb 12 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 4.46 | 18,903 | 84,307 | 18,903 | |
Feb 12 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Grant | A | 0.00 | 10,500 | 11 | 26,769 | 16.3 K to 26.8 K (+64.54 %) |
Feb 05 2008 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Payment of Exercise | F | 5.27 | 831 | 4,379 | 16,269 | 17.1 K to 16.3 K (-4.86 %) |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 7.43 | 22,283 | 165,563 | 22,283 | |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 6.77 | 22,697 | 153,659 | 22,697 | |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 7.43 | 13,717 | 101,917 | 13,717 | |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 6.77 | 17,203 | 116,464 | 17,203 | |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Sell | D | 8.11 | 500 | 4,055 | 17,100 | 17.6 K to 17.1 K (-2.84 %) |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Grant | A | 0.00 | 7,000 | 7 | 17,600 | 10.6 K to 17.6 K (+66.04 %) |
Feb 21 2007 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Grant | A | 0.00 | 5,600 | 6 | 10,600 | 5 K to 10.6 K (+112.00 %) |
Feb 21 2006 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | A | 6.77 | 39,900 | 270,123 | 39,900 | |
Feb 21 2006 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Grant | A | 0.00 | 5,600 | 6 | 12,721 | 7.1 K to 12.7 K (+78.64 %) |
May 12 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | P | 7.51 | 500 | 3,755 | 5,000 | 4.5 K to 5 K (+11.11 %) |
May 12 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | P | 7.52 | 300 | 2,256 | 4,500 | 4.2 K to 4.5 K (+7.14 %) |
May 12 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | P | 7.53 | 1,100 | 8,283 | 4,200 | 3.1 K to 4.2 K (+35.48 %) |
May 12 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | P | 7.55 | 3,100 | 23,405 | 3,100 | 0 to 3.1 K |
Feb 18 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 10.27 | 14,166 | 145,485 | 14,166 | |
Feb 18 2005 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 10.27 | 5,834 | 59,915 | 5,834 | |
Jul 14 2004 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 9.41 | 22,125 | 208,196 | 22,125 | |
Jul 14 2004 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 5.40 | 99,133 | 535,318 | 99,133 | |
Jul 14 2004 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 9.41 | 5,875 | 55,284 | 5,875 | |
Jul 14 2004 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | A | 5.40 | 65,867 | 355,682 | 65,867 |
Page: 1